CUE BIOPHARMA INC (CUE)

US22978P1066 - Common Stock

1.05  -0.04 (-3.67%)

Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to CUE. CUE was compared to 564 industry peers in the Biotechnology industry. CUE has a bad profitability rating. Also its financial health evaluation is rather negative. CUE shows excellent growth, but is valued quite expensive already.



Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year CUE has reported negative net income.
In the past year CUE has reported a negative cash flow from operations.
CUE had negative earnings in each of the past 5 years.
CUE had a negative operating cash flow in each of the past 5 years.

1.2 Ratios

The Return On Assets of CUE (-99.56%) is worse than 76.30% of its industry peers.
With a Return On Equity value of -175.87%, CUE is not doing good in the industry: 66.97% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -99.56%
ROE -175.87%
ROIC N/A
ROA(3y)-64.49%
ROA(5y)-57.94%
ROE(3y)-94.98%
ROE(5y)-81.79%
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

CUE does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A

More info and screens

2

2. Health

2.1 Basic Checks

CUE does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, CUE has more shares outstanding
The number of shares outstanding for CUE has been increased compared to 5 years ago.
Compared to 1 year ago, CUE has a worse debt to assets ratio.

2.2 Solvency

CUE has an Altman-Z score of -10.85. This is a bad value and indicates that CUE is not financially healthy and even has some risk of bankruptcy.
CUE's Altman-Z score of -10.85 is on the low side compared to the rest of the industry. CUE is outperformed by 75.58% of its industry peers.
CUE has a Debt/Equity ratio of 0.05. This is a healthy value indicating a solid balance between debt and equity.
With a Debt to Equity ratio value of 0.05, CUE is not doing good in the industry: 62.48% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity 0.05
Debt/FCF N/A
Altman-Z -10.85
ROIC/WACCN/A
WACC10.93%

2.3 Liquidity

A Current Ratio of 2.22 indicates that CUE has no problem at all paying its short term obligations.
CUE has a Current ratio of 2.22. This is in the lower half of the industry: CUE underperforms 73.97% of its industry peers.
A Quick Ratio of 2.22 indicates that CUE has no problem at all paying its short term obligations.
CUE has a worse Quick ratio (2.22) than 72.17% of its industry peers.
Industry RankSector Rank
Current Ratio 2.22
Quick Ratio 2.22

More info and screens

7

3. Growth

3.1 Past

CUE shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 24.17%, which is quite impressive.
CUE shows a strong growth in Revenue. In the last year, the Revenue has grown by 149.53%.
CUE shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 36.94% yearly.
EPS 1Y (TTM)24.17%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%29.17%
Revenue 1Y (TTM)149.53%
Revenue growth 3Y20.34%
Revenue growth 5Y36.94%
Sales Q2Q%58.86%

3.2 Future

Based on estimates for the next years, CUE will show a quite strong growth in Earnings Per Share. The EPS will grow by 9.35% on average per year.
CUE is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 51.67% yearly.
EPS Next Y30.66%
EPS Next 2Y22.46%
EPS Next 3Y16.45%
EPS Next 5Y9.35%
Revenue Next Year94.59%
Revenue Next 2Y46.98%
Revenue Next 3Y57.85%
Revenue Next 5Y51.67%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for CUE. In the last year negative earnings were reported.
Also next year CUE is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A

4.3 Compensation for Growth

CUE's earnings are expected to grow with 16.45% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y22.46%
EPS Next 3Y16.45%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for CUE!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CUE BIOPHARMA INC

NASDAQ:CUE (1/2/2025, 10:05:20 AM)

1.05

-0.04 (-3.67%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-14 2024-11-14/amc
Earnings (Next)N/A N/A
Inst Owners26.6%
Inst Owner Change1.49%
Ins Owners0.55%
Ins Owner Change1.34%
Market Cap66.52M
Analysts86.67
Price Target3.67 (249.52%)
Short Float %1.71%
Short Ratio1.76
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)21.42%
Min EPS beat(2)12.56%
Max EPS beat(2)30.27%
EPS beat(4)3
Avg EPS beat(4)12.94%
Min EPS beat(4)-3.28%
Max EPS beat(4)30.27%
EPS beat(8)6
Avg EPS beat(8)8.49%
EPS beat(12)9
Avg EPS beat(12)11.2%
EPS beat(16)10
Avg EPS beat(16)8.91%
Revenue beat(2)2
Avg Revenue beat(2)110.74%
Min Revenue beat(2)104.15%
Max Revenue beat(2)117.33%
Revenue beat(4)4
Avg Revenue beat(4)69.17%
Min Revenue beat(4)15.03%
Max Revenue beat(4)117.33%
Revenue beat(8)7
Avg Revenue beat(8)45.46%
Revenue beat(12)8
Avg Revenue beat(12)24.15%
Revenue beat(16)11
Avg Revenue beat(16)35.72%
PT rev (1m)0%
PT rev (3m)-14.29%
EPS NQ rev (1m)0%
EPS NQ rev (3m)57.84%
EPS NY rev (1m)0%
EPS NY rev (3m)8.56%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)58.02%
Revenue NY rev (1m)-15.71%
Revenue NY rev (3m)-15.51%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 6.98
P/FCF N/A
P/OCF N/A
P/B 2.62
P/tB 2.62
EV/EBITDA N/A
EPS(TTM)-0.91
EYN/A
EPS(NY)-0.56
Fwd EYN/A
FCF(TTM)-0.6
FCFYN/A
OCF(TTM)-0.6
OCFYN/A
SpS0.15
BVpS0.4
TBVpS0.4
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -99.56%
ROE -175.87%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-64.49%
ROA(5y)-57.94%
ROE(3y)-94.98%
ROE(5y)-81.79%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.21
Health
Industry RankSector Rank
Debt/Equity 0.05
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 15.42%
Cap/Sales 0.67%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.22
Quick Ratio 2.22
Altman-Z -10.85
F-Score4
WACC10.93%
ROIC/WACCN/A
Cap/Depr(3y)30.23%
Cap/Depr(5y)30.7%
Cap/Sales(3y)6.56%
Cap/Sales(5y)8.04%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)24.17%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%29.17%
EPS Next Y30.66%
EPS Next 2Y22.46%
EPS Next 3Y16.45%
EPS Next 5Y9.35%
Revenue 1Y (TTM)149.53%
Revenue growth 3Y20.34%
Revenue growth 5Y36.94%
Sales Q2Q%58.86%
Revenue Next Year94.59%
Revenue Next 2Y46.98%
Revenue Next 3Y57.85%
Revenue Next 5Y51.67%
EBIT growth 1Y14.23%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-9.42%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y8.99%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y8.77%
OCF growth 3YN/A
OCF growth 5YN/A